Multiple regions of E6AP (UBE3A) contribute to interaction with papillomavirus E6 proteins and the activation of ubiquitin ligase activity

Autoři: Camille M. Drews aff001;  Nicole Brimer aff001;  Scott B. Vande Pol aff001
Působiště autorů: Department of Pathology, University of Virginia, Charlottesville, Virginia, United States of America aff001
Vyšlo v časopise: Multiple regions of E6AP (UBE3A) contribute to interaction with papillomavirus E6 proteins and the activation of ubiquitin ligase activity. PLoS Pathog 16(1): e32767. doi:10.1371/journal.ppat.1008295
Kategorie: Research Article
doi: 10.1371/journal.ppat.1008295


The HECT domain E3 ubiquitin ligase E6AP (UBE3A) is critical for the development of human papillomavirus (HPV) associated cancers, the neurodevelopment disorder Angelman Syndrome, and some cases of autism spectrum disorders. How E6AP recognizes its cellular targets and how its ubiquitin ligase activity is triggered remain poorly understood, and HPV E6 proteins are models for these processes. We examined diverse E6 proteins from human and non-human papillomaviruses and identified two different modes of interaction between E6 and E6AP. In Type I interactions, E6 can interact directly with the LXXLL peptide motif alone of E6AP (isolated from the rest of E6AP), and then recruit cellular substrates such as p53. In Type II interactions, E6 proteins require additional auxiliary regions of E6AP in either the amino terminus or in the carboxy-terminal HECT domain to interact with the LXXLL peptide motif of E6AP. A region of E6AP amino-terminal to the LXXLL peptide motif both augments association with E6 proteins and is required for E6 proteins to trigger ubiquitin ligase activity in the carboxy-terminal HECT ubiquitin ligase domain of E6AP. In Type I interactions, E6 can associate with E6AP and recruit p53, but a Type II interaction is required for the degradation of p53 or NHERF1. Interestingly, different E6 proteins varied in E6AP auxiliary regions that contributed to enhanced association, indicating evolutionary drift in the formation of Type II interactions. This classification of E6-E6AP interaction types and identification of a region in the E6AP amino terminus that is important for both E6 association and stimulation of ubiquitin ligase activity will inform future structural data of the E6-E6AP complex and future studies aiming to interfere with the activity of the E6-E6AP complex.

Klíčová slova:

DNA-binding proteins – Human papillomavirus – Papillomaviruses – Protein domains – Protein interactions – Sequence motif analysis – Ubiquitin ligases – Yeast


1. Bergvall M, Melendy T, Archambault J. The E1 proteins. Virology. 2013;445(1–2):35–56. Epub 2013/09/14. doi: 10.1016/j.virol.2013.07.020 24029589.

2. McBride AA. The papillomavirus E2 proteins. Virology. 2013;445(1–2):57–79. doi: 10.1016/j.virol.2013.06.006 23849793.

3. Bernard HU. Regulatory elements in the viral genome. Virology. 2013;445(1–2):197–204. Epub 2013/06/04. doi: 10.1016/j.virol.2013.04.035 23725692.

4. Schwartz S. Papillomavirus transcripts and posttranscriptional regulation. Virology. 2013;445(1–2):187–96. Epub 2013/05/28. doi: 10.1016/j.virol.2013.04.034 23706315.

5. Vande Pol S, Howley PM. A bovine papillomavirus constitutive enhancer is negatively regulated by the E2 repressor through competitive binding for a cellular factor. J Virol. 1990;64(5420):5420–9.

6. Thierry F, Howley PM. Functional analysis of E2-mediated repression of the HPV18 P105 promoter. New Biol. 1991;3(90):90–100.

7. Romanczuk H, Howley PM. Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proc Natl Acad Sci U S A. 1992;89(7):3159–63. doi: 10.1073/pnas.89.7.3159 1313584

8. Thierry F. Transcriptional regulation of the papillomavirus oncogenes by cellular and viral transcription factors in cervical carcinoma. Virology. 2009;384(2):375–9. Epub 2008/12/10. doi: 10.1016/j.virol.2008.11.014 19064276.

9. Sandler AB, Vande Pol SB, Spalholz BA. Repression of bovine papillomavirus type 1 transcription by the E1 replication protein. J Virol. 1993;67(9):5079–87. 8394436

10. Vande Pol S, Howley P. Negative regulation of the bovine papillomavirus E5, E6, and E7 oncogenes by the viral E1 and E2 genes. J Virol. 1995;69:395–402. 7983735

11. Meyers C, Frattini MG, Hudson JB, Laimins LA. Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science. 1992;257(5072):971–3. Epub 1992/08/14. doi: 10.1126/science.1323879 1323879.

12. Meyers C, Mayer TJ, Ozbun MA. Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA. J Virol. 1997;71(10):7381–6. Epub 1997/10/06. 9311816.

13. Roman A, Munger K. The papillomavirus E7 proteins. Virology. 2013;445:138–68. doi: 10.1016/j.virol.2013.04.013 23731972.

14. Vande Pol SB, Klingelhutz AJ. Papillomavirus E6 oncoproteins. Virology. 2013;445(1–2):115–37. doi: 10.1016/j.virol.2013.04.026 23711382.

15. Davey NE, Trave G, Gibson TJ. How viruses hijack cell regulation. Trends Biochem Sci. 2011;36(3):159–69. Epub 2010/12/15. doi: 10.1016/j.tibs.2010.10.002 21146412.

16. White EA. Manipulation of Epithelial Differentiation by HPV Oncoproteins. Viruses. 2019;11(4). Epub 2019/04/25. doi: 10.3390/v11040369 31013597.

17. Egawa N, Doorbar J. The low-risk papillomaviruses. Virus Res. 2017;231:119–27. Epub 2017/01/04. doi: 10.1016/j.virusres.2016.12.017 28040475.

18. zur Hausen H. Papillomaviruses in the causation of human cancers—a brief historical account. Virology. 2009;384(2):260–5. Epub 2009/01/13. doi: 10.1016/j.virol.2008.11.046 19135222.

19. Saraiya M, Unger ER, Thompson TD, Lynch CF, Hernandez BY, Lyu CW, et al. US Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV Vaccines. 2015;107(6):djv086-djv. doi: 10.1093/jnci/djv086 25925419

20. Chen JJ, Hong Y, Rustamzadeh E, Baleja JD, Androphy EJ. Identification of an alpha helical motif sufficient for association with papillomavirus E6. J Biol Chem. 1998;273(22):13537–44. doi: 10.1074/jbc.273.22.13537 9593689

21. Elston RC, Napthine S, Doorbar J. The identification of a conserved binding motif within human papillomavirus type 16 E6 binding peptides, E6AP and E6BP. J Gen Virol. 1998;79(Pt 2):371–4.

22. Vande Pol SB, Brown MC, Turner CE. Association of Bovine Papillomavirus Type 1 E6 oncoprotein with the focal adhesion protein paxillin through a conserved protein interaction motif. Oncogene. 1998;16(1):43–52. doi: 10.1038/sj.onc.1201504 9467941

23. Zanier K, Charbonnier S, Sidi AO, McEwen AG, Ferrario MG, Poussin-Courmontagne P, et al. Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins. Science. 2013;339(6120):694–8. doi: 10.1126/science.1229934 23393263.

24. Kishino T, Lalande M, Wagstaff J. UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet. 1997;15(1):70–3. Epub 1997/01/01. doi: 10.1038/ng0197-70 8988171.

25. Matsuura T, Sutcliffe JS, Fang P, Galjaard RJ, Jiang YH, Benton CS, et al. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet. 1997;15(1):74–7. Epub 1997/01/01. doi: 10.1038/ng0197-74 8988172.

26. Hogart A, Wu D, LaSalle JM, Schanen NC. The comorbidity of autism with the genomic disorders of chromosome 15q11.2-q13. Neurobiol Dis. 2010;38(2):181–91. Epub 2008/10/09. doi: 10.1016/j.nbd.2008.08.011 18840528.

27. Brimer N, Drews CM, Vande Pol SB. Association of papillomavirus E6 proteins with either MAML1 or E6AP clusters E6 proteins by structure, function, and evolutionary relatedness. PLoS Pathog. 2017;13(12):e1006781. doi: 10.1371/journal.ppat.1006781 29281732.

28. Brimer N, Lyons C, Wallberg AE, Vande Pol SB. Cutaneous papillomavirus E6 oncoproteins associate with MAML1 to repress transactivation and NOTCH signaling. Oncogene. 2012;31(43):4639–46. doi: 10.1038/onc.2011.589 22249263.

29. Meyers JM, Spangle JM, Munger K. The HPV8 E6 protein interferes with NOTCH activation during keratinocyte differentiation. J Virol. 2013. doi: 10.1128/JVI.02527-12 23365452.

30. Tan MJ, White EA, Sowa ME, Harper JW, Aster JC, Howley PM. Cutaneous beta-human papillomavirus E6 proteins bind Mastermind-like coactivators and repress Notch signaling. Proc Natl Acad Sci U S A. 2012;109(23):E1473–80. Epub 2012/05/02. doi: 10.1073/pnas.1205991109 22547818.

31. Wade R, Brimer N, Vande Pol S. Transformation by bovine papillomavirus type 1 E6 requires paxillin. J Virol. 2008;82(12):5962–6. doi: 10.1128/JVI.02747-07 18385245.

32. Vande Pol S. Papillomavirus E6 Oncoproteins Take Common Structural Approaches to Solve Different Biological Problems. PLoS Pathog. 2015;11(10):e1005138. doi: 10.1371/journal.ppat.1005138 26470018.

33. Scheffner M, Huibregtse JM, Howley PM. Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc Natl Acad Sci U S A. 1994;91(19):8797–801. doi: 10.1073/pnas.91.19.8797 8090726

34. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 1993;75(3):495–505. doi: 10.1016/0092-8674(93)90384-3 8221889

35. Huibregtse JM, Scheffner M, Howley PM. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. Embo J. 1991;10(13):4129–35. 1661671

36. Huibregtse JM, Scheffner M, Howley PM. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol. 1993;13(2):775–84. doi: 10.1128/mcb.13.2.775 8380895

37. Huibregtse JM, Scheffner M, Howley PM. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol Cell Biol. 1993;13(8):4918–27. doi: 10.1128/mcb.13.8.4918 8393140

38. Scheffner M, Nuber U, Huibregtse JM. Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature. 1995;373(6509):81–3. doi: 10.1038/373081a0 7800044

39. Ansari T, Brimer N, Vande Pol SB. Peptide interactions stabilize and restructure human papillomavirus type 16 E6 to interact with p53. J Virol. 2012;86(20):11386–91. doi: 10.1128/JVI.01236-12 22896608.

40. Martinez-Zapien D, Ruiz FX, Poirson J, Mitschler A, Ramirez J, Forster A, et al. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53. Nature. 2016. doi: 10.1038/nature16481 26789255.

41. Drews CM, Case S, Vande Pol SB. E6 proteins from high-risk HPV, low-risk HPV, and animal papillomaviruses activate the Wnt/beta-catenin pathway through E6AP-dependent degradation of NHERF1. PLoS Pathog. 2019;15(4):e1007575. Epub 2019/04/20. doi: 10.1371/journal.ppat.1007575 31002735.

42. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene. 2003;22(38):5938–45. doi: 10.1038/sj.onc.1206894 12955072.

43. Kelley ML, Keiger KE, Lee CJ, Huibregtse JM. The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase. J Virol. 2005;79(6):3737–47. doi: 10.1128/JVI.79.6.3737-3747.2005 15731267.

44. Cooper B, Schneider S, Bohl J, Jiang Y, Beaudet A, Vande Pol S. Requirement of E6AP and the features of human papillomavirus E6 necessary to support degradation of p53. Virology. 2003;306(1):87–99. doi: 10.1016/s0042-6822(02)00012-0 12620801.

45. Brimer N, Lyons C, Vande Pol SB. Association of E6AP (UBE3A) with human papillomavirus type 11 E6 protein. Virology. 2007;358(2):303–10. doi: 10.1016/j.virol.2006.08.038 17023019.

46. Tomaic V, Pim D, Banks L. The stability of the human papillomavirus E6 oncoprotein is E6AP dependent. Virology. 2009;393(1):7–10. Epub 2009/08/25. doi: 10.1016/j.virol.2009.07.029 19700180.

47. Bohl J, Das K, Dasgupta B, Vande Pol SB. Competitive binding to a charged leucine motif represses transformation by a papillomavirus E6 oncoprotein. Virology. 2000;271(1):163–70. doi: 10.1006/viro.2000.0316 10814581

48. Ostrow RS, LaBresh KV, Faras AJ. Characterization of the complete RhPV 1 genomic sequence and an integration locus from a metastatic tumor. Virology. 1991;181(1):424–9. doi: 10.1016/0042-6822(91)90519-h 1847267.

49. Mortensen F, Schneider D, Barbic T, Sladewska-Marquardt A, Kuhnle S, Marx A, et al. Role of ubiquitin and the HPV E6 oncoprotein in E6AP-mediated ubiquitination. Proc Natl Acad Sci U S A. 2015;112(32):9872–7. Epub 2015/07/29. doi: 10.1073/pnas.1505923112 26216987.

50. Sailer C, Offensperger F, Julier A, Kammer KM, Walker-Gray R, Gold MG, et al. Structural dynamics of the E6AP/UBE3A-E6-p53 enzyme-substrate complex. Nature communications. 2018;9(1):4441. Epub 2018/10/27. doi: 10.1038/s41467-018-06953-0 30361475.

51. Charbonnier S, Zanier K, Masson M, Trave G. Capturing protein-protein complexes at equilibrium: The holdup comparative chromatographic retention assay. Protein Expr Purif. 2006. doi: 10.1016/j.pep.2006.06.010 16884919.

52. Sekaric P, Cherry JJ, Androphy EJ. Binding of human papillomavirus type 16 E6 to E6AP is not required for activation of hTERT. J Virol. 2008;82(1):71–6. doi: 10.1128/JVI.01776-07 17942561.

53. Massimi P, Shai A, Lambert P, Banks L. HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background. Oncogene. 2008;27(12):1800–4. doi: 10.1038/sj.onc.1210810 17934525.

54. Gyuris J, Golemis E, Chertkov H, Brent R. Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2. Cell. 1993;75(4):791–803. doi: 10.1016/0092-8674(93)90498-f 8242750

55. Sikorski RS, Hieter P. A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics. 1989;122(1):19–27. 2659436

Článek vyšel v časopise

PLOS Pathogens

2020 Číslo 1
Nejčtenější tento týden
Nejčtenější v tomto čísle

Zvyšte si kvalifikaci online z pohodlí domova

Konsenzuální postupy v léčbě močových infekcí
nový kurz

Hereditární TTR amyloidóza – vzácné, nebo jen neodhalené onemocnění? 2. díl

Současné možnosti v léčbě psoriázy

Svět praktické medicíny 4/2022 (znalostní test z časopisu)

COVID-19 up to date
Autoři: doc. MUDr. Vladimír Koblížek, Ph.D., MUDr. Mikuláš Skála, prof. MUDr. František Kopřiva, Ph.D., prof. MUDr. Roman Prymula, CSc., Ph.D.

Všechny kurzy
Kurzy Podcasty Doporučená témata Časopisy
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.


Nemáte účet?  Registrujte se